# The Trendlines Group raises S$14.03 million through placement of new shares, resulting in net proceeds of S$13.34 million

## Placement subscribers include cornerstone investor B. Braun Melsungen AG, as well as prominent institutional and corporate investors

MISGAV, Israel, 25 October, 2017 -- The Trendlines Group Ltd. (the "Group" or "Trendlines") (SGX: 42T; OTCQX: TRNLY), a leading Israeli investment and innovation commercialization company focused on early-stage, high growth innovation-based medical and agricultural technologies, today announced it completed the allotment and issuance of 100 million new ordinary shares at a Placement Price of S$0.1403 per share for gross proceeds of S$14.03 million. Trendlines will receive net proceeds of approximately S$13.34 million (approximately US$ 9.8 million) in exchange for the issuance of the new shares.

The placement was well subscribed by a good mix of institutional, corporate and individual investors. B. Braun Melsungen AG, the cornerstone investor in Trendlines' November 2015 IPO, participated in this placement, maintaining its shareholding in The Trendlines Group. In addition, subscribers in the placement include prominent corporate and individual investors, Asdew Acquisitions Pte Ltd, Island Asset Management Pte Ltd, ICH Capital Pte Ltd, Lumiere Capital Limited, Azure Capital Pte Ltd, Emerald Investment Management Pte Ltd and others.

The net proceeds of the placement will be used for the Group's general working capital and direct and indirect investment in new, prospective and existing portfolio companies.

With the placement completed, and as announced in the placement announcement on 10 October 2017, the Group is conducting a strategic review in respect of its operations. The scope of the review includes the portfolio held by the Group and the operation of its business with a view to reduce costs, increase efficiency and enhance shareholder value, including the possible implementation of a dividend policy. The review will be carried out in compliance with all applicable laws, rules and regulations, including the Catalist Rules, and further announcement(s) in relation to the strategic review will be made if required by the Catalist Rules.

Steve Rhodes, Chairman and CEO of Trendlines, remarked that "the success of this placement demonstrates the ongoing support among investors for the unique model we have established to build great companies around innovative medical and agricultural technologies. We are

especially pleased that one of our foremost international partners, B. Braun Melsungen AG, participated in the placement, indicating their continuing commitment to the growth of Trendlines and our work together in the medical device sector. In addition, we welcome new Asia-based investors, further strengthening Trendlines' position in the Asian medical sector."

Commenting on recent corporate developments, Trendlines' Chairman and CEO Todd Dollinger noted, "We have had two exits since September of last year, and have also announced two additional potential exits – Vensica Medical Ltd. and MitrAssist Ltd. Investor interest is healthy on both the portfolio company level and in the Group, and the funds raised in this placement give Trendlines increased financial resources and flexibility in investing in promising companies – we have already started seven new companies this year – and we are working on moving certain portfolio companies toward exit transactions."

**About The Trendlines Group Ltd.**

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfil its mission to improve the human condition. An intensely hands-on investor, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

---

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).